Glucagon-like peptide-1 agonism - GLP-1, common in obesity medicines - is not essential to weight management, according to preclinical research led by Richard DiMarchi and Matthias Tschöp, with funding from their startup company Bluewater Biosciences.
Yeah, I’m not trusting an article that makes a lot of claims that are contrary to my lived experience and everything else I’ve ever read but cites nothing.